MXPA04009236A - Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades. - Google Patents

Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.

Info

Publication number
MXPA04009236A
MXPA04009236A MXPA04009236A MXPA04009236A MXPA04009236A MX PA04009236 A MXPA04009236 A MX PA04009236A MX PA04009236 A MXPA04009236 A MX PA04009236A MX PA04009236 A MXPA04009236 A MX PA04009236A MX PA04009236 A MXPA04009236 A MX PA04009236A
Authority
MX
Mexico
Prior art keywords
comorbidites
diabetes
pioglitazone
treatment
composition
Prior art date
Application number
MXPA04009236A
Other languages
English (en)
Inventor
Jorge Luis Rosado Loria
Original Assignee
Jorge Luis Rosado Loria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36090288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA04009236(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jorge Luis Rosado Loria filed Critical Jorge Luis Rosado Loria
Priority to MXPA04009236A priority Critical patent/MXPA04009236A/es
Priority to PCT/MX2005/000057 priority patent/WO2006033568A1/es
Publication of MXPA04009236A publication Critical patent/MXPA04009236A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

La presente invencion esta relacionada con la industria farmaceutica en general y con la industria de la manufactura de productos farmaceuticos para el tratamiento de diabetes y sus comorbilidades. Las ventajas de la presente invencion con respecto de las composiciones del estado de la tecnica radica en que el presente hace posible un manejo a largo plazo de un cuadro diabetico para mantener un control glucemico adecuado; logrando un efecto mas potente sobre la hiperglucemia permitiendo reducir las dosis y por lo tanto los efectos colaterales individuales de las drogas; mejora la sensibilidad a la insulina de los receptores beta pancreaticos corrigiendo simultaneamente los trastornos de secrecion de insulina y favorece el metabolismo lipidico, mejorando asimismo el perfil del mismo en el plasma sanguineo. La composicion esta formada por un agente hipoglucemiante y un agente antihiperglucemiante. Siendo glimepirida el primero y pioglitazona el segundo. La pioglitazona se encuentra en la composicion en una cantidad entre 5 y 2500 mg y la glimepirida entre 1 y 250 mg.
MXPA04009236A 2004-09-23 2004-09-23 Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades. MXPA04009236A (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MXPA04009236A MXPA04009236A (es) 2004-09-23 2004-09-23 Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
PCT/MX2005/000057 WO2006033568A1 (es) 2004-09-23 2005-07-18 Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MXPA04009236A MXPA04009236A (es) 2004-09-23 2004-09-23 Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.

Publications (1)

Publication Number Publication Date
MXPA04009236A true MXPA04009236A (es) 2006-03-27

Family

ID=36090288

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04009236A MXPA04009236A (es) 2004-09-23 2004-09-23 Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.

Country Status (2)

Country Link
MX (1) MXPA04009236A (es)
WO (1) WO2006033568A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
WO2006033568A1 (es) 2006-03-30

Similar Documents

Publication Publication Date Title
CR20210552A (es) Inhibidores del inflamasoma nlrp3
UA96441C2 (ru) Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
MX2009012000A (es) Derivados de pirazol heteroarilo sustituidos utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis.
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное
EA017764B8 (ru) Фармацевтическая композиция, способ ее получения и способ лечения вирусных заболеваний с ее использованием
MXPA05009933A (es) Composiciones que comprenden acidos grasos y aminoacidos.
MX2009003305A (es) Inhibidores de co-transportador de glucosa de sodio 2 y metodo para su uso.
WO2006120574A3 (en) Analogs of 4-hydroxyisoleucine and uses thereof
HK1117138A1 (en) Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
MXPA05007485A (es) Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
BR0314996A (pt) Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
WO2008120070A3 (en) 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) displaying hepatoprotective, hypoammoniemic and detoxic action, a method for its production and a pharmaceutical composition based thereon
NZ593461A (en) Exendin for treating diabetes and reducing body weight
MY146388A (en) Thiazole pyrazolopyrimidines as crfi receptor antagonists
WO2007123511A3 (en) Dosing regimens for the treatment of cancer
CY1111369T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολη και παρακεταμολη
WO2008071790A3 (en) Novel compositions and uses thereof
Nguyen et al. The influence of single-dose and short-term administration of quercetin on the pharmacokinetics of midazolam in humans
DK1482919T3 (da) Farmaceutisk sammensætning til blodsukkerkontrol hos patienter med type 2 diabetes
WO2007070355A3 (en) Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
MXPA04009236A (es) Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
NO20050398L (no) Nye adenosinanaloger og deres anvendelse som farmasoytiske midler
TNSN06072A1 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
UA94975C2 (ru) Композиция и ее применение для лечения гипергликемии и связанных с ней болезней
ATE396997T1 (de) Substituierte, bizyklische 8-pyrrolidino- benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or assignment
GD Licence granted